Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program.
colocated care
direct-acting antivirals (DAAs)
hepatitis C virus infection (HCV)
opioid agonist therapy (OAT)
people who inject drugs (PWID)
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
24
04
2020
accepted:
15
07
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few real-world examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era. We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island's only nonprofit methadone maintenance program. Of 275 who initiated DAAs, the mean age (range) was 43 (22-71) years, 34.5% were female, 57.5% had genotype 1a, 23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232/273), while modified intent-to-treat SVR was 93.2% (232/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty reinfections were identified over 375.5 person-years of follow-up (rate, 7.99/100 person-years). The median time to first reinfection (interquartile range) was 128 (85.25-202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps, differing across 11 RI insurers, taking 45-120 minutes per patient. DAA treatment was effective among a marginalized population in an urban colocated OAT/HCV program. Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in the United States.
Sections du résumé
BACKGROUND
BACKGROUND
A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few real-world examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era.
METHODS
METHODS
We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island's only nonprofit methadone maintenance program.
RESULTS
RESULTS
Of 275 who initiated DAAs, the mean age (range) was 43 (22-71) years, 34.5% were female, 57.5% had genotype 1a, 23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232/273), while modified intent-to-treat SVR was 93.2% (232/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty reinfections were identified over 375.5 person-years of follow-up (rate, 7.99/100 person-years). The median time to first reinfection (interquartile range) was 128 (85.25-202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps, differing across 11 RI insurers, taking 45-120 minutes per patient.
CONCLUSIONS
CONCLUSIONS
DAA treatment was effective among a marginalized population in an urban colocated OAT/HCV program. Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in the United States.
Identifiants
pubmed: 33072802
doi: 10.1093/ofid/ofaa310
pii: ofaa310
pmc: PMC7550646
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa310Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
PLoS Med. 2019 Nov 19;16(11):e1002963
pubmed: 31743335
R I Med J (2013). 2014 Jul 01;97(7):19-24
pubmed: 24983016
Int J Drug Policy. 2019 Oct;72:129-137
pubmed: 30962036
Clin Infect Dis. 2020 Jun 10;70(12):2695-2702
pubmed: 31346609
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Hepat Mon. 2013 Aug 17;13(8):e12411
pubmed: 24069039
J Subst Abuse Treat. 2019 May;100:45-51
pubmed: 30898327
J Viral Hepat. 2017 May;24(5):359-370
pubmed: 28027424
MMWR Recomm Rep. 2020 Apr 10;69(2):1-17
pubmed: 32271723
JAMA Intern Med. 2014 Dec;174(12):1974-81
pubmed: 25347412
J Hepatol. 2020 Apr;72(4):643-657
pubmed: 31785345
N Engl J Med. 2018 Jul 5;379(1):7-8
pubmed: 29972744
Clin Infect Dis. 2020 Feb 03;:
pubmed: 32009165
Int J Drug Policy. 2018 Sep;59:76-84
pubmed: 30048877
Clin Infect Dis. 2020 May 23;70(11):2355-2365
pubmed: 31513710
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
Infect Dis Clin North Am. 2018 Jun;32(2):281-292
pubmed: 29778256
Hepatology. 2011 Jun;53(6):1789-91
pubmed: 21520197
Ann Intern Med. 2015 Aug 4;163(3):215-23
pubmed: 26120969
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767
pubmed: 30245064
Clin Infect Dis. 2019 Jul 2;69(2):323-331
pubmed: 30329042
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
J Subst Abuse Treat. 2017 Apr;75:49-53
pubmed: 28237054
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409